¼¼°èÀÇ ¸¶ÀÌÅ©·Î´Ïµé ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå
Microneedle Drug Delivery Systems
»óǰÄÚµå : 1775014
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 391 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è ¸¶ÀÌÅ©·Î´Ïµé ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº 2030³â±îÁö 85¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 59¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¸¶ÀÌÅ©·Î´Ïµé ¾à¹°Àü´Þ ½Ã½ºÅÛ ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 6.3%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 85¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Áß°ø ¸¶ÀÌÅ©·Î´ÏµéÀº CAGR 8.4%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á±îÁö 26¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °íü ¸¶ÀÌÅ©·Î´Ïµé ºÎ¹®ÀÇ ¼ºÀåÀº ºÐ¼® ±â°£Áß CAGR 4.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 16¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÇÑÆí, Áß±¹Àº CAGR 10.2%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµÈ´Ù

¹Ì±¹ÀÇ ¸¶ÀÌÅ©·Î´Ïµé ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº 2024³â¿¡ 16¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 18¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 10.2%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 3.0%¿Í 6.2%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.1%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ¸¶ÀÌÅ©·Î´Ïµé ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¸¶ÀÌÅ©·Î´Ïµé ¾à¹°Àü´Þ ½Ã½ºÅÛÀ̶õ?

¸¶ÀÌÅ©·Î´Ïµé ¾à¹°Àü´Þ½Ã½ºÅÛ(MDDS)Àº ÅëÁõÀÌ ¾ø´Â Ãʹ̼¼ ¹Ù´ÃÀ» ÀÌ¿ëÇÏ¿© ÇǺθ¦ ÅëÇØ ¾à¹°À» Åõ¿©ÇÏ´Â »õ·Î¿î ¹æ¹ýÀÔ´Ï´Ù. ÀϹÝÀûÀ¸·Î 25-1000 ¸¶ÀÌÅ©·Î¹ÌÅÍ ±æÀÌÀÇ ÃʼÒÇü ¹Ù´ÃÀÌ ÇǺÎÀÇ °¡Àå ¹Ù±ùÃþ(°¢ÁúÃþ)¿¡ ¹Ì¼¼ÇÑ È¨À» ¸¸µé¾î ÅëÁõ°ú ºÒÆíÇÔÀ» ÃÖ¼ÒÈ­Çϸ鼭 ¾à¹°À» ÇǺγª Ç÷·ù·Î Á÷Á¢ Àü´ÞÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. ƯÈ÷ ¹é½Å, Àν¶¸° Àü´Þ, ±âŸ »ý¹°ÇÐÀû Á¦Á¦ µîÀÇ ºÐ¾ß¿¡¼­ ÁÖ»ç µî ±âÁ¸ ¾à¹° Åõ¿© ¹æ¹ýÀ» ´ëüÇÒ ¼ö ÀÖ´Â ºñħ½ÀÀû ¹æ¹ýÀ¸·Î °¢±¤¹Þ°í ÀÖ½À´Ï´Ù.

MDDS´Â ±¹¼Ò ¹× Àü½Å ¾à¹° Àü´Þ¿¡ ¸ðµÎ »ç¿ëÇÒ ¼ö Àֱ⠶§¹®¿¡ ±× Àû¿ë ¹üÀ§°¡ ³Ð½À´Ï´Ù. ±âÁ¸ÀÇ ÁÖ»ç¹Ù´ÃÀ̳ª °æ±¸¿ë ¾à¹°¿¡ ºñÇØ ¸¶ÀÌÅ©·Î´ÏµéÀÇ ÁÖ¿ä ÀåÁ¡Àº »ç¿ëÀÇ ¿ëÀ̼º, ÅëÁõ °¨¼Ò, ƯÈ÷ ´ç´¢º´°ú °°ÀÌ Áֻ縦 ÀÚÁÖ ¸Â¾Æ¾ß ÇÏ´Â ¸¸¼º Áúȯ¿¡ ´ëÇÑ È¯ÀÚÀÇ ¼øÀÀµµ Çâ»óÀÔ´Ï´Ù. ¶ÇÇÑ, ¸¶ÀÌÅ©·Î´ÏµéÀº ¾à¹° ¹æÃâÀ» Á¤È®ÇÏ°Ô Á¦¾îÇÒ ¼ö ÀÖ°í ¼ÒÈ­±â°üÀ» ¿ìȸÇÏ¿© »ýü ÀÌ¿ë·üÀ» Çâ»ó½ÃÄÑ À§»êÀ̳ª È¿¼Ò¿¡ ÀÇÇØ ºÐÇØµÉ ¼ö ÀÖ´Â ´Ü¹éÁú, ¹é½Å ¹× ±âŸ ¾à¹°¿¡ ÀÌ»óÀûÀÔ´Ï´Ù.

ÀÚ°¡ Åõ¿© Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ÀçÅÃÄ¡·á ¼Ö·ç¼ÇÀÇ ºÎ»óÀ¸·Î ¸¶ÀÌÅ©·Î´Ïµé ±â¼ú¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ȯÀÚ ÀÔÀå¿¡¼­´Â Á¤±âÀûÀÎ ÀÇ»ç ¹æ¹®À̳ª ÀÓ»ó ÇöÀå¿¡¼­ÀÇ Áֻ簡 ÇÊ¿ä ¾ø±â ¶§¹®¿¡ º¸´Ù Æí¾ÈÇϰí ÀÚÀ²ÀûÀÎ Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ ±â¼úÀº Á¦¾àȸ»ç¿¡ Çõ½ÅÀûÀÌ°í ºñ¿ë È¿À²ÀûÀÎ ¾à¹° Àü´Þ ¹æ½ÄÀ» Á¦°øÇÏ¿© ȯÀÚ ¸¸Á·µµ¿Í º¹¾à ¼øÀÀµµ¸¦ Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.

¸¶ÀÌÅ©·Î´Ïµé ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä µ¿ÇâÀº?

¸¶ÀÌÅ©·Î´Ïµé ¾à¹°Àü´Þ ½ÃÀåÀº ƯÈ÷ MDDSÀÇ È¿´É°ú Àû¿ëÀ» Çâ»ó½Ã۱â À§ÇÑ Àç·á ¹× ½Å±â¼ú °³¹ß¿¡¼­ ¸î °¡Áö ÁÖ¿ä Æ®·»µå¸¦ ¸ñ°ÝÇϰí ÀÖ½À´Ï´Ù. °¡Àå Áß¿äÇÑ Æ®·»µå Áß Çϳª´Â ¸¶ÀÌÅ©·Î´Ïµé µðÀÚÀΰú ¼ÒÀçÀÇ ÁøÈ­ÀÔ´Ï´Ù. ±âÁ¸ÀÇ ¸¶ÀÌÅ©·Î´ÏµéÀº ÁÖ·Î ±Ý¼ÓÀ̳ª ½Ç¸®ÄÜÀ¸·Î ¸¸µé¾îÁ³Áö¸¸, ÃÖ±Ù ±â¼ú Çõ½ÅÀ¸·Î ÀÎÇØ »ýºÐÇØ¼º Æú¸®¸Ó°¡ µµÀÔµÇ¾î ¾ÈÀü¼ºÀÌ ´õ¿í °­È­µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ »ýºÐÇØ¼º ¸¶ÀÌÅ©·Î´ÏµéÀº ¾à¹° Åõ¿© ÈÄ ÇÇÇÏ¿¡¼­ ¿ëÇØµÇ¾î Á¦°ÅÀÇ Çʿ伺À» ÁÙÀÌ°í °¨¿°ÀÇ À§ÇèÀ» ÃÖ¼ÒÈ­ÇÕ´Ï´Ù. »ýºÐÇØ¼º ¸¶ÀÌÅ©·Î´Ïµé·ÎÀÇ Ãß¼¼´Â ¸¶ÀÌÅ©·Î´Ïµé ±â¹Ý ½Ã½ºÅÛÀÇ ¾ÈÀü¼º°ú ÆíÀǼºÀ» Å©°Ô Çâ»ó½Ãų °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¶Ç ´Ù¸¥ Å« È帧Àº Àå±â°£¿¡ °ÉÃÄ ÅëÁõ ¾øÀÌ È¿À²ÀûÀ¸·Î ¾à¹°À» Àü´ÞÇÒ ¼ö ÀÖ´Â ¸¶ÀÌÅ©·Î´Ïµé ÆÐÄ¡ÀÇ °³¹ßÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÆÐÄ¡´Â ¾à¹°À» Áö¼ÓÀûÀ¸·Î Àü´ÞÇÒ ¼ö ÀÖ¾î ȯÀÚ´Â ¹Ýº¹ÀûÀÎ °³ÀÔ ¾øÀ̵µ ÀϰüµÈ ¿ë·®À» Áö¼ÓÀûÀ¸·Î Åõ¿©¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ƯÈ÷ Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ°ú ¾à¹° Àü´ÞÀÌ Áß¿äÇÑ ´ç´¢º´°ú °°Àº ¸¸¼º Áúȯ°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù. ¼­¹æÇü ¿Ü¿¡µµ, ÀÌ·¯ÇÑ ÆÐÄ¡´Â »ç¿ëÇϱ⠽±°í, ±âÁ¸ ÁÖ»çÁ¦¿¡ ºñÇØ ȯÀÚ°¡ ´õ ½±°Ô ¹Þ¾ÆµéÀÏ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀ¸·Î ÀÎÇØ ÀçÅà ġ·á¿¡ ¸¶ÀÌÅ©·Î´Ïµé ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ Ã¤ÅÃÀÌ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ¸¶ÀÌÅ©·Î´ÏµéÀ» ÅëÇØ Åõ¿©ÇÒ ¼ö ÀÖ´Â ¾à¹°ÀÇ ¹üÀ§¸¦ È®´ëÇÏ´Â µ¥¿¡µµ °ü½ÉÀÌ ÁýÁߵǰí ÀÖ½À´Ï´Ù. ¸¶ÀÌÅ©·Î´Ïµé ½Ã½ºÅÛÀº Ãʱ⿡´Â ¹é½Å°ú Àν¶¸°¿¡ »ç¿ëµÇ¾úÁö¸¸, ³ª³ë±â¼ú°ú ¾àÁ¦ÇÐÀÇ ¹ßÀüÀ¸·Î º¸´Ù ±¤¹üÀ§ÇÑ »ý¹°ÇÐÀû Á¦Á¦ ¹× ÀúºÐÀÚ ¾à¹°ÀÇ Àü´ÞÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ¿¬±¸ÀÚµéÀº Ç×ü, ÆéŸÀ̵å, ÇÙ»ê°ú °°Àº º¹ÀâÇÑ ºÐÀÚ¸¦ ¸¶ÀÌÅ©·Î´Ïµé ½Ã½ºÅÛ¿¡ ÅëÇÕÇÏ´Â ¹æ¹ýÀ» ¸ð»öÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÀ¿ë ¹üÀ§ÀÇ È®ÀåÀº ¸¶ÀÌÅ©·Î´Ïµé ±â¼úÀÇ »õ·Î¿î ½ÃÀå, ƯÈ÷ ¾Ï, ÀÚ°¡¸é¿ªÁúȯ, À¯ÀüÀÚ Ä¡·á µî »õ·Î¿î ½ÃÀåÀ» °³Ã´ÇÒ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

¸¶ÀÌÅ©·Î´Ïµé µå·° µô¸®¹ö¸® ½Ã½ºÅÛÀÇ ¹®Á¦Á¡°ú ÇѰè´Â?

¸¹Àº ÀåÁ¡¿¡µµ ºÒ±¸Çϰí, ¸¶ÀÌÅ©·Î´Ïµé ¾à¹°Àü´Þ ½Ã½ºÅÛÀº º¸±ÞÀ» ¹æÇØÇÏ´Â ¸î °¡Áö ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÁÖ¿ä °úÁ¦ Áß Çϳª´Â ÀÌ ¸¶ÀÌÅ©·Î Å©±âÀÇ ¹Ù´Ã Á¦Á¶ÀÇ º¹À⼺ÀÔ´Ï´Ù. ¸¶ÀÌÅ©·Î´Ïµé¿¡ »ç¿ëµÇ´Â Àç·á´Â ÁøÈ­Çϰí ÀÖÁö¸¸, ÀϰüµÈ °íǰÁú·Î Á¦Á¶ÇÏ´Â °ÍÀº ¿©ÀüÈ÷ ¾î·Æ°í ºñ¿ëÀÌ ¸¹ÀÌ µì´Ï´Ù. ÀÌ·¯ÇÑ ÃʼÒÇüÀÇ ³¯Ä«·Î¿î ±¸Á¶¸¦ ¸¸µå´Â µ¥ ÇÊ¿äÇÑ Á¤¹Ðµµ´Â Á¦Á¶ ½Ã¼³ÀÌ Æ¯¼ö Àåºñ¿¡ ÅõÀÚÇØ¾ß ÇÑ´Ù´Â °ÍÀ» ÀǹÌÇϸç, ÀÌ´Â Á¦Á¶ ºñ¿ë°ú ½Ã°£À» Áõ°¡½Ãų ¼ö ÀÖ½À´Ï´Ù.

¶Ç ´Ù¸¥ ÇѰè´Â °³Àθ¶´Ù ´Ù¸¥ ÇǺΠÅõ°ú¼º°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù. ÇǺΠµÎ²², ¼öºÐ º¸Ãæ, ÇǺΠÁúȯ À¯¹« µîÀÇ ¿äÀÎÀÌ ¾à¹°ÀÇ ÇǺΠÈí¼öÀ²¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. À̸¦ ±Øº¹Çϱâ À§Çؼ­´Â ¸¶ÀÌÅ©·Î´ÏµéÀ» ƯÁ¤ ȯÀÚ±º°ú ¾à¹°ÀÇ À¯Çü¿¡ ¸Â°Ô Á¶Á¤ÇØ¾ß Çϸç, À̸¦ À§Çؼ­´Â ±¤¹üÀ§ÇÑ Á¶»ç¿Í ÀÓ»ó½ÃÇèÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¶ÇÇÑ, ¸¶ÀÌÅ©·Î´ÏµéÀº ¼ÒÈ­±â°üÀ» ¿ìȸÇÏ¿© È¿¼Ò ºÐÇØ¸¦ ÇÇÇÒ ¼ö ÀÖÁö¸¸, ¸ðµç ¾à¹°, ƯÈ÷ Á¤È®Çϰí ÅëÁ¦µÈ Èí¼ö ÇÁ·ÎÆÄÀÏÀ» ÇÊ¿ä·Î ÇÏ´Â ¾à¹°¿¡ ÀûÇÕÇÏÁö ¾ÊÀ» ¼ö ÀÖ½À´Ï´Ù.

¸¶ÀÌÅ©·Î´Ïµé ¾à¹°Àü´Þ½Ã½ºÅÛÀÇ ¾à»ç ½ÂÀÎ °úÁ¤µµ °úÁ¦ÀÔ´Ï´Ù. ¸¶ÀÌÅ©·Î´ÏµéÀº ±âÁ¸ Áֻ纸´Ù ´ú ħ½ÀÀûÀ̶ó°í ¿©°ÜÁöÁö¸¸, ¿©ÀüÈ÷ ½Åü¿Í Á÷Á¢ÀûÀ¸·Î »óÈ£ÀÛ¿ëÇÏ´Â ¾à¹° Àü´ÞÀÇ ÇÑ ÇüÅÂÀÓ¿¡´Â º¯ÇÔÀÌ ¾ø½À´Ï´Ù. Áï, ³Î¸® »ç¿ëµÇ±â À§Çؼ­´Â ¾ö°ÝÇÑ ÀÓ»ó½ÃÇè°ú ±ÔÁ¦Àû °ËÅ並 °ÅÃÄ¾ß ÇÕ´Ï´Ù. ƯÁ¤ Áö¿ª¿¡¼­´Â ¸¶ÀÌÅ©·Î´Ïµé ±ÔÁ¦ °æ·Î°¡ È®¸³µÇ¾î ÀÖÁö ¾Ê¾Æ ½ÃÀå ÁøÀÔÀÌ ´Ê¾îÁö°í ±â¼ú Çõ½ÅÀÇ ¼Óµµ°¡ ´À·ÁÁú ¼ö ÀÖ½À´Ï´Ù.

¸¶ÀÌÅ©·Î´Ïµé ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀº ¹«¾ùÀΰ¡?

¸¶ÀÌÅ©·Î´Ïµé ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀåÀº ¾à¹° Àü´Þ ±â¼úÀÇ ¹ßÀü, ÀÚ°¡ Åõ¿© Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¸¸¼º ÁúȯÀÇ È®»ê µî ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Á¦¾àȸ»çµéÀÌ º¸´Ù È¿°úÀûÀ̰í ȯÀÚ Ä£È­ÀûÀÎ ¾à¹° Àü´Þ ¼Ö·ç¼ÇÀ» °³¹ßÇϰíÀÚ ÇÏ´Â °¡¿îµ¥, ¸¶ÀÌÅ©·Î´ÏµéÀº ƯÈ÷ »ý¹°ÇÐÀû Á¦Á¦, ¹é½Å, Àν¶¸°¿¡¼­ ÀüÅëÀûÀÎ ÁÖÀÔ ¹æ½Ä¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ´ë¾ÈÀ» Á¦°øÇÕ´Ï´Ù. ¸¶ÀÌÅ©·Î´Ïµé °ü·Ã ÆíÀǼº°ú »ç¿ëÀÇ ¿ëÀ̼º, ƯÈ÷ ÀÚ°¡ Åõ¿© Ä¡·áÀÇ ¿ëÀ̼ºÀº ¼ÒºñÀÚ ¹× ÀÇ·á ºÎ¹® ¸ðµÎ¿¡¼­ ¸¶ÀÌÅ©·Î´Ïµé äÅÃÀÇ ÁÖ¿ä ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ¹Ù´ÃÀ» »ç¿ëÇÏÁö ¾Ê´Â ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ ÃßÁøÀº ¸¶ÀÌÅ©·Î´Ïµé ±â¼úÀÇ ¼ºÀå¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ȯÀÚÀÇ ºÒÆíÇÔ°ú ¹Ù´Ã¿¡ ´ëÇÑ µÎ·Á¿òÀº ƯÈ÷ ´ç´¢º´°ú °°Àº ¸¸¼º ÁúȯÀ̳ª ¹é½Å Åõ¿© ½Ã Ä¡·á ¼øÀÀµµ¸¦ ÀúÇØÇÏ´Â ¿À·£ À庮À¸·Î ÀÛ¿ëÇØ ¿Ô½À´Ï´Ù. ¸¶ÀÌÅ©·Î´ÏµéÀº ȯÀڵ鿡°Ô °íÅëÀÌ Àû°í »ç¿ëÇϱ⠽¬¿î ¼Ö·ç¼ÇÀ» Á¦°øÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇØ°áÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÓ»ó ȯ°æÀ̳ª Àü¹®°¡ÀÇ µµ¿ò ¾øÀÌ Áý¿¡¼­ ¾à¹°À» Åõ¿©ÇÒ ¼ö ÀÖ´Ù´Â Á¡Àº ÀÇ·áºñ Áõ°¡¿Í ÀçÅÃÄ¡·á·ÎÀÇ ÀüȯÀÌ °¡¼ÓÈ­µÇ°í ÀÖ´Â »óȲ¿¡¼­ ƯÈ÷ ¸Å·ÂÀûÀÔ´Ï´Ù.

±â¼ú ¹ßÀüµµ ½ÃÀå È®´ë¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. »ýºÐÇØ¼º °íºÐÀÚ ¹× ³ª³ë±â¼úÀÇ µµÀÔ°ú °°Àº ¸¶ÀÌÅ©·Î´Ïµé Àç·áÀÇ Çõ½ÅÀº ¸¶ÀÌÅ©·Î´Ïµé ±â¹Ý ½Ã½ºÅÛÀÇ ¾ÈÀü¼º, À¯È¿¼º ¹× È®À强À» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾à¹° ¼­¹æÇü ¸¶ÀÌÅ©·Î´Ïµé ÆÐÄ¡ÀÇ °³¹ßÀº ƯÈ÷ Áö¼ÓÀûÀÎ ¾à¹° Åõ¿©°¡ ÇÊ¿äÇÑ Áõ»ó¿¡ ´ëÇÑ »õ·Î¿î ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ¾Ï, ´ç´¢º´, ¸¸¼ºÅëÁõ µî Àå±âÀûÀÌ°í ¾ÈÁ¤ÀûÀÎ ¾à¹° Åõ¿©°¡ ÇÊ¿äÇÑ ÁúȯÀÇ Ä¡·á¿¡¼­ ÁöÁö¸¦ ¹Þ°í ÀÖ½À´Ï´Ù.

¸¶Áö¸·À¸·Î, Á¤ºÎÀÇ Áö¿ø°ú R&D¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡´Â ¸¶ÀÌÅ©·Î´Ïµé ±â¼úÀÇ ¹ßÀüÀ» °¡¼ÓÈ­Çϰí ÀÖÀ¸¸ç, FDA ¹× EMA¿Í °°Àº ±ÔÁ¦ ±â°üÀÌ ´õ ¸¹Àº ¸¶ÀÌÅ©·Î´Ïµé ±â¹Ý Á¦Ç°À» ½ÂÀÎÇϱ⠽ÃÀÛÇÔ¿¡ µû¶ó ½ÃÀå ¼ºÀåÀÌ °¡¼ÓÈ­µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¶ÇÇÑ, º¸´Ù È¿À²ÀûÀÎ ¾à¹° Àü´Þ ¼Ö·ç¼Ç °³¹ß¿¡ ´ëÇÑ Á¦¾àȸ»ç¿Í ½ºÅ¸Æ®¾÷ÀÇ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¸¶ÀÌÅ©·Î´Ïµé ±â¼ú¿¡ ´ëÇÑ ÅõÀÚµµ °è¼Ó Áõ°¡ÇÒ °ÍÀÔ´Ï´Ù. Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛÀÌ ºñ¿ë Àý°¨°ú ȯÀÚ ¿¹ÈÄ °³¼±À» À§ÇÑ Çõ½ÅÀûÀÎ ¹æ¹ýÀ» ¸ð»öÇϰí ÀÖ´Â °¡¿îµ¥, ¸¶ÀÌÅ©·Î´Ïµé ¾à¹° Àü´Þ ½Ã½ºÅÛÀº Â÷¼¼´ë ¾à¹° Àü´Þ ±â¼úÀÇ ÃÖÀü¼±¿¡ ¼­°Ô µÉ °ÍÀÔ´Ï´Ù.

°á·ÐÀûÀ¸·Î, ¸¶ÀÌÅ©·Î´Ïµé ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº ¾à¹° Àü´Þ ±â¼úÀÇ ¹ßÀü, ºñħ½ÀÀû ¹× ÀÚ°¡ Åõ¿© Ä¡·á¿¡ ´ëÇÑ È¯ÀÚ ¼±È£µµ, Àå±âÀûÀ̰í Áö¼ÓÀûÀÎ Åõ¾àÀÌ ÇÊ¿äÇÑ ¸¸¼º Áúȯ Áõ°¡·Î ÀÎÇØ ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ¸¶ÀÌÅ©·Î´Ïµé ±â¼úÀÌ °è¼Ó ¹ßÀüÇÔ¿¡ µû¶ó ´Ù¾çÇÑ Ä¡·á ºÐ¾ß¿¡ Æø³Ð°Ô Àû¿ëµÇ¸é¼­ ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀÔ´Ï´Ù. Á¦Á¶, ±ÔÁ¦, Èí¼ö¿Í °ü·ÃµÈ ¹®Á¦¸¦ ±Øº¹ÇÏ´Â µ¥ °è¼Ó ÁýÁßÇÑ´Ù¸é, ¸¶ÀÌÅ©·Î´Ïµé ±â¹Ý ¼Ö·ç¼ÇÀº ÇâÈÄ ¸î³â³»¿¡ ¾à¹° Àü´ÞÀÇ Ç¥ÁØÀûÀÎ ¹æ¹ýÀÌ µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

À¯Çü(Áß°ø ¸¶ÀÌÅ©·Î´Ïµé, °íü ¸¶ÀÌÅ©·Î´Ïµé, ÄÚÆÃ ¸¶ÀÌÅ©·Î´Ïµé, ¿ëÇØ ¸¶ÀÌÅ©·Î´Ïµé, ±âŸ À¯Çü);¼ÒÀç(±Ý¼Ó ¼ÒÀç, ½Ç¸®ÄÜ ¼ÒÀç, Æú¸®¸Ó ¼ÒÀç, ±âŸ ¼ÒÀç);¿ëµµ(¾à¹°Àü´Þ ¿ëµµ, ¹é½Å Àü´Þ ¿ëµµ, ¾Ï Ä¡·á ¿ëµµ, ÅëÁõ °ü¸® ¿ëµµ, ÇǺΰú ¿ëµµ, ±âŸ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Microneedle Drug Delivery Systems Market to Reach US$8.5 Billion by 2030

The global market for Microneedle Drug Delivery Systems estimated at US$5.9 Billion in the year 2024, is expected to reach US$8.5 Billion by 2030, growing at a CAGR of 6.3% over the analysis period 2024-2030. Hollow Microneedles, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Solid Microneedles segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 10.2% CAGR

The Microneedle Drug Delivery Systems market in the U.S. is estimated at US$1.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 10.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Microneedle Drug Delivery Systems Market - Key Trends & Drivers Summarized

What Are Microneedle Drug Delivery Systems and Why Are They Gaining Popularity?

Microneedle drug delivery systems (MDDS) are a novel method of administering medications through the skin using tiny, painless needles. These micro-sized needles, typically ranging from 25 to 1000 micrometers in length, create micro-channels in the skin’s outermost layer (the stratum corneum), allowing drugs to be delivered directly into the skin or bloodstream with minimal pain or discomfort. MDDS has gained traction as a non-invasive alternative to traditional drug administration methods, such as injections, particularly in fields like vaccines, insulin delivery, and other biologics.

MDDS can be used for both local and systemic drug delivery, making them versatile in their application. The primary advantages of microneedles over traditional needles or oral medications are the ease of use, reduced pain, and enhanced patient compliance, particularly for chronic conditions requiring frequent injections, such as diabetes. Additionally, microneedles allow for precise control over drug release and offer improved bioavailability by bypassing the digestive system, making them ideal for proteins, vaccines, and other drugs that may be degraded by stomach acids or enzymes.

The growing demand for self-administered treatments and the rise of home healthcare solutions are driving interest in microneedle technology. For patients, this method offers greater comfort and autonomy, as it eliminates the need for regular doctor visits or injections in a clinical setting. Moreover, the technology provides pharmaceutical companies with an innovative, cost-effective approach to drug delivery that can improve patient satisfaction and adherence.

What Are the Key Trends Shaping the Microneedle Drug Delivery Systems Market?

The microneedle drug delivery market is witnessing several key trends, particularly in the development of materials and new technologies to enhance the effectiveness and application of MDDS. One of the most significant trends is the evolution of microneedle designs and materials. Traditional microneedles were often made from metals or silicon, but recent innovations have introduced bio-degradable polymers, which provide an additional level of safety. These biodegradable microneedles dissolve under the skin after the drug is delivered, reducing the need for removal and minimizing the risk of infection. The trend toward bio-degradable microneedles is expected to drive significant advancements in the safety and convenience of microneedle-based systems.

Another major trend is the development of microneedle patches that enable painless and efficient drug delivery over an extended period. These patches can deliver drugs continuously, ensuring that patients receive a consistent dose without the need for repeated interventions. This trend is especially relevant for chronic conditions such as diabetes, where constant monitoring and drug delivery are crucial. In addition to their sustained release capabilities, these patches are easy to use, making them more acceptable for patients compared to traditional injection methods. Such advancements are significantly increasing the adoption of microneedle drug delivery systems for at-home treatments.

Additionally, there is a growing focus on expanding the range of drugs that can be delivered using microneedles. While microneedle systems were initially used for vaccines and insulin, advances in nanotechnology and drug formulations are enabling the delivery of a broader range of biologics and small-molecule drugs. Researchers are exploring ways to incorporate complex molecules, such as antibodies, peptides, and nucleic acids, into microneedle systems. This broadening of applications is expected to unlock new markets for microneedle technology, especially in the treatment of cancer, autoimmune diseases, and gene therapies.

What Are the Challenges and Limitations of Microneedle Drug Delivery Systems?

Despite their many advantages, microneedle drug delivery systems face several challenges that can hinder their widespread adoption. One of the primary challenges is the complexity of manufacturing these micro-sized needles. While the materials used for microneedles have evolved, producing them at a consistent, high quality remains difficult and costly. The precision required to create these tiny, sharp structures means that manufacturing facilities need to invest in specialized equipment, which can increase production costs and time.

Another limitation is related to the skin’s varying permeability across different individuals. Factors such as skin thickness, hydration, and the presence of skin diseases can affect how well the drug is absorbed through the skin. To overcome this, microneedles need to be tailored for specific patient groups or types of drugs, which requires extensive research and clinical testing. Furthermore, although microneedles can bypass the digestive system and avoid enzymatic degradation, they may not be suitable for all drugs, particularly those that require precise and controlled absorption profiles.

The regulatory approval process for microneedle drug delivery systems is also a challenge. While microneedles are considered less invasive than traditional injections, they are still a form of drug delivery that interacts directly with the body. This means they must undergo rigorous clinical trials and regulatory scrutiny before they can be widely used. The lack of established regulatory pathways for microneedles in certain regions may delay market entry and slow the pace of innovation.

What Are the Main Growth Drivers for the Microneedle Drug Delivery Systems Market?

The growth in the microneedle drug delivery systems market is driven by several key factors, including advancements in drug delivery technologies, increasing demand for self-administered treatments, and the growing prevalence of chronic diseases. As pharmaceutical companies seek to develop more effective and patient-friendly drug delivery solutions, microneedles offer an appealing alternative to traditional injection methods, particularly for biologic drugs, vaccines, and insulin. The convenience and ease of use associated with microneedles, especially in self-administered treatments, is a major driver for their adoption in both the consumer and healthcare sectors.

In addition, the push for needle-free drug delivery systems is significantly contributing to the growth of microneedle technologies. Patient discomfort and fear of needles have been long-standing barriers to treatment adherence, especially in chronic conditions like diabetes or when administering vaccines. Microneedles address these concerns by offering a painless, easy-to-use solution that is less intimidating for patients. The ability to deliver drugs at home, without requiring a clinical setting or professional assistance, is especially appealing in the context of increasing healthcare costs and the shift toward home-based care.

Technological advancements are also playing a key role in the market's expansion. Innovations in microneedle materials, such as biodegradable polymers and the incorporation of nanotechnology, are improving the safety, effectiveness, and scalability of microneedle-based systems. Moreover, the development of microneedle patches for sustained drug release is creating new opportunities in the market, particularly for conditions that require continuous drug administration. This trend is gaining traction in the treatment of conditions such as cancer, diabetes, and chronic pain, where long-term, consistent medication delivery is necessary.

Lastly, government support and increasing investments in research and development are accelerating the progress of microneedle technology. As regulatory agencies, such as the FDA and EMA, begin to approve more microneedle-based products, the market is expected to see faster growth. Additionally, growing interest from pharmaceutical companies and start-ups to develop more efficient drug delivery solutions will continue to fuel investment in microneedle technology. As healthcare systems worldwide look for innovative ways to reduce costs and improve patient outcomes, microneedle drug delivery systems will remain at the forefront of the next generation of drug delivery technologies.

In conclusion, the microneedle drug delivery system market is growing rapidly due to advancements in drug delivery technologies, patient preferences for non-invasive and self-administered treatments, and the increasing prevalence of chronic diseases that require long-term, consistent medication. As microneedle technology continues to evolve, its broader application across various therapeutic areas will further drive growth. The continued focus on overcoming manufacturing, regulatory, and absorption challenges will enable microneedle-based solutions to become a standard method for drug delivery in the years to come.

SCOPE OF STUDY:

The report analyzes the Microneedle Drug Delivery Systems market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Hollow Microneedles, Solid Microneedles, Coated Microneedles, Dissolving, Microneedles, Other Types); Material (Metal Material, Silicon Material, Polymer Material, Other Materials); Application (Drug Delivery Application, Vaccine Delivery Application, Cancer Therapy Application, Pain Management Application, Dermatology Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â